Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investor Events
  • Pre-market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
April 18, 2022 8:48 AM 2 min read

4 Stocks Under $5 Insiders Are Aggressively Buying

by Lisa Levin Benzinga Editor
Follow

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Black Diamond Therapeutics

  • The Trade: Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) 10% owner BB Biotech Ag acquired a total of 252,556 shares at an average price of $3.48. To acquire these shares, it cost $879.82 thousand.
  • What’s Happening: Wedbush, last month, downgraded Black Diamond Therapeutic from Outperform to Neutral.
  • What Black Diamond Therapeutics Does: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies.

Hemisphere Media Group

  • The Trade: Hemisphere Media Group, Inc. (NASDAQ:HMTV) 10% owner Debra Fine acquired a total of 215,094 shares at an average price of $4.14. The insider spent around $890.02 thousand to buy those shares.
  • What’s Happening: Hemisphere Media, last month, posted Q4 sales of $56.80 million.
  • What Hemisphere Media Group Does: Hemisphere Media Group Inc is a Spanish-language media company. It owns and operates several Spanish-language networks and content production platform, including movie and telenovela channels, Hispanic entertainment genres, and the cable television networks.

Also check this: Executives Buy More Than $400M Of 3 Stocks

Don’t forget to check out our premarket coverage here .

ReWalk Robotics

OncoCyte

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.


Posted In:
Long IdeasNewsPenny StocksInsider TradesMarketsTrading IdeasPenny Stocks Insider Buying
BDTX Logo
BDTXBlack Diamond Therapeutics Inc
$2.250.90%
Overview
  • The Trade: ReWalk Robotics Ltd. (NASDAQ:RWLK) 10% owner Lind Global MacRo Fund Lp acquired a total of 242,251 shares at an average price of $2.35. To acquire these shares, it cost around $569.37 thousand.
  • What’s Happening: ReWalk Robotics, during February, posted Q4 sales of $1.20 million.
  • What ReWalk Robotics Does: ReWalk Robotics Ltd is an Israel based medical device company.
  • The Trade: OncoCyte Corporation (NASDAQ:OCX) 10% owner Broadwood Capital Inc acquired a total of 6,003,752 shares at an average price of $1.33. The insider spent $8 million to buy those shares.
  • What’s Happening: Oncocyte recently reported pricing of registered direct offering of 11.765 million shares.
  • What OncoCyte Does: OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer.
BDTX Logo
BDTXBlack Diamond Therapeutics Inc
$2.250.90%
Overview
Comments
Loading...